Sunday, 27 September 2026 Every NSE & BSE announcement, by company
ALFA Filings Every announcement, straight from the exchange
Financial Results · Q1 FY27

Kimia Biosciences Q1 FY27 Results: Net Profit ₹0.4 Cr, Down 33.3% YoY

Kimia Biosciences Ltd reported revenue from operations of ₹20.7 Cr (-12.3% YoY) and net profit of ₹0.4 Cr (-33.3% YoY) for Q1 FY27.

Q1 FY27 at a glance · ₹ crore
MetricQ1 FY27Q4 FY26Q1 FY26
Revenue from operations20.727.223.6
Other income0.11.00.8
Total income20.828.224.4
Profit before exceptional items & tax0.51.80.7
Profit before tax0.51.80.7
Net profit0.40.40.6
Operating margin2.4%6.4%2.9%

A dash means the filing did not report that period; n/m means not meaningful (margin on near-zero revenue). Growth is not shown when either period was a loss. Operating profit excludes other income.

Growth
Net profit, year on year-33.30%
Net profit, quarter on quarter+0.00%
Revenue, year on year-12.30%
Operating profit, year on year+500.00%
Operating profit, quarter on quarter-50.00%
Source

BSE results filing, NSE: LAURLOR. Figures extracted from the filing.

Read the filing ↗

Kimia Biosciences Ltd: key numbers

Share price
₹30.77
Market cap
₹145.6 Cr
Revenue (annual)
₹114.9 Cr
Net profit (annual)
₹7.43 Cr
P/E (TTM)
20.3×Sector 50.4×
Promoter holding
74.94%+0.00% QoQ
FII holding
0.00%Current quarter

Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.

More from Kimia Biosciences Ltd

All →
20:39 IST BSE
Other Announcement

Kimia Biosciences Other Announcement

The company filed its quarterly shareholding pattern under Regulation 31(1)(b) for the period ended March 31, 2026.

16:26 IST BSE
Annual General Meeting

Kimia Biosciences Annual General Meeting

Kimia Biosciences Limited has submitted its notice for the 33rd Annual General Meeting scheduled for September 28, 2026, along with the Annual Report for FY 2025-26.

18:47 IST BSE
Board Meeting Outcome

Kimia Biosciences Board Meeting Outcome

Kimia Biosciences' board meeting outcome includes director appointments, approval of the 33rd AGM notice, and increased borrowing/investment limits. The board also adopted the annual report.